-
More additional affiliations for the FDA to gather information. In the news recently have been other agreements with companies such as Blue Cross and others who will be providing data to also study the effects of drugs through medical record information in their files, based on claims, etc. No...
Posted to
The Medical Quack .... by Barbara Duck
by
The Medical Quack
on
08-18-2008
Filed under:
Filed under: Medically Related, Technology, Insurance, Pharma/FDA News, health insurance, healthcare IT, Pharma, Biotech, FDA, Medco, Pharmacogonomics
-
The meaning of advantage is below. Who knows what might be uncovered next as this may or may not be just a Merck issue, but as documents and other items of years past surface, this is what we have, sell, sell, sell, and it's perhaps not unlikely that some of these items and issues could exist...
-
Does this say that the FDA is perhaps not as trusted as we might like the agency to be? On the other hand is it possible to entrust any agency to this level today, and that might be more to the point. There are so many areas that need to come to focus and with all the information we have...
-
Right now according to the Wall Street Journal, patients who have enjoyed an open relationship are worried that this could all change under management from Roche. Is bigger always better? Recently in the news Genentech is not happy with the offer and may hold out for more. Anyone that...
-
As marketing intensity increases, there are some strange bedfellows emerging and who knows what could be the next affiliation we may read about? Ask your Abbott representative about Crestor. BD Under the terms of the agreement, Abbott will obtain the non-exclusive right to promote CRESTOR...
-
One reason stated is convenience, more on every corner, like the gas stations. To take advantage of some of the other low cost benefits, there may be a longer driving distance. A while back I had a conversation with someone from CVS, and there are shoppers who visit every store, one for a...
-
Some things in sales don't change no matter what field you are in and Pharma is no different, sales are made by building relationships, in other words, people do business with people they like, so the peer articles maybe could be just a little off target. I spent over 20 years in outside sales...
-
The patent is stated not to expire until 2010 and this will put a 30 hold at the FDA to grant approval. This one should prove interesting to follow and see where the infringement occurs. BD LONDON -(Dow Jones)- Sanofi-Aventis SA (SNY) has launched a legal action against Canadian generic drugmaker...
-
Discussed here is the recent law in Massachusetts relative to gifts, etc. just recently passed. Being the CEO of BIO, the biotech industry trade group, of course there's an interest in not having funds diminished, but also addresses the interest of the public. With all the recent Pharma...
-
One more Pharma company joins You Tube Channels, GSK, but this post makes a very good point, no embedding, I agree here, what’s up with Glaxo not allowing one to embed! Also as mentioned, where’s the publicity as Eye on the FDA reports that he’s subscriber number 8! Is big pharma still a...
-
One CEO comes out and states how biotech will be the new focus for Glaxo, as in a related story whereby patients will require genetic testing for their AIDS drug, Ziagen. In the future I’m sure there will be more about big pharma and their biotech strategies as personalized medicine continues...
-
There is more potential downsizing going on with big Pharma. Just yesterday an article related to the number of plants set to the be closed in the US. I might guess this could be the sign of more outsourcing overseas. BD Last year, Bristol-Myers Squibb said it was cutting some...
-
More business action with big pharma and the biotech industry, although Roche and Genentech already are invested together and have worked on conjunction on research projects. Roche acquired a majority in Genentech in 1990 and currently owns 55.9% of all outstanding shares. Roche...
-
Congress and the Department of Justice now join the inquiry about the FDA actions investigating the alleged falsification of test records. This is where joint committees could also stand to shed some light here as both Australia and the UK are working with the FDA in reference to drug factories...
-
Update: Are 3 minds better than one? It certainly appears this could be the case, at least when it comes to clinical trials and getting the right type of participants to enroll and some forecasting to make sure the drugs will succeed. What is the target here, the big crystal...